8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Apr 27, 2026·SEC
Erasca, Inc.(ERAS)Earnings, Financials & Key Ratios
ERAS•NASDAQ
Price updated Jun 19, 2026
AboutErasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$128M+27.0%
- Net Income-$125M+23.0%
- EPS (Diluted)-0.44+36.2%
- ROE-33.27%+23.8%
ERAS Key Insights
Erasca, Inc. (ERAS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 21.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 11.9x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ERAS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ERAS Price & Volume
Erasca, Inc. (ERAS) stock price & volume — 10-year historical chart
Loading chart...
ERAS Growth Metrics
Erasca, Inc. (ERAS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-75.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-50%
Return on Capital
10 Years-51.66%
5 Years-40.63%
3 Years-35.99%
Last Year-31.33%
ERAS Recent Earnings
Erasca, Inc. (ERAS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.11+4.7%
$0.12
Rev
—
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.10+9.1%
$0.11
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.11+0.0%
$0.11
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.12+0.0%
$0.12
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.11vs $0.12+4.7% | — |
| Q2 2026 | Mar 12, 2026 | $0.10vs $0.11+9.1% | — |
| Q4 2025 | Nov 12, 2025 | $0.11vs $0.11+0.0% | — |
| Q3 2025 | Aug 12, 2025 | $0.12vs $0.12+0.0% | — |
Based on last 12 quarters of dataView full earnings history →
ERAS Peer Comparison
Erasca, Inc. (ERAS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 |
Compare ERAS vs Peers
Erasca, Inc. (ERAS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ERAS Income Statement
Erasca, Inc. (ERAS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 829K | 2.64M | 3.73M | 0 | 3.11M | 1.47M |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -829K▲ 0% | -2.64M▼ 218.6% | -3.73M▼ 41.3% | 0▲ 100.0% | -3.11M▲ 0% | -1.47M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | -218.58% | -41.31% | 100% | - | - |
Operating Expenses | 13.29M | 109.25M | 124.05M | 244.81M | 137.79M | 179.59M | 128.3M | 141.72M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 3.68M | 7.96M | 22.62M | 32.99M | 37.7M | 41.73M | 38.55M | 39.54M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 9.62M | 101.3M | 73.92M | 112.46M | 103.82M | 115.36M | 92.85M | 94.15M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 27.52M | 99.36M | -3.73M | 22.5M | -3.11M | 534K |
Operating Income | -13.29M▲ 0% | -109.25M▼ 721.8% | -124.88M▼ 14.3% | -247.45M▼ 98.1% | -141.53M▲ 42.8% | -179.59M▼ 26.9% | -131.41M▲ 26.8% | -143.19M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -721.81% | -14.31% | -98.15% | 42.81% | -26.89% | 26.83% | - |
EBITDA | -12.98M | -108.71M | -124.05M | -244.81M | -137.79M | -175.78M | -128.3M | -140.18M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -737.28% | -14.11% | -97.34% | 43.71% | -27.57% | 27.01% | 18.85% |
D&A (Non-Cash Add-back) | 310K | 540K | 829K | 2.64M | 3.73M | 3.81M | 3.11M | 3.01M |
EBIT | -13.29M | -37.51M | -122.76M | -242.81M | -125.04M | -157.09M | -131.41M | -131.75M |
Net Interest Income | 1.3M | 336K | 190K | -196.46M | 16.71M | 20.09M | 16.61M | 16.32M |
Interest Income | 1.3M | 336K | 190K | 4.9M | 16.71M | 20.09M | 16.61M | 16.32M |
Interest Expense | 0 | 0 | 0 | 201.36M | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.25M | 7.59M | 2.12M | 4.64M | 16.48M | 17.94M | 6.86M | -133.83M |
Pretax Income | -12.04M▲ 0% | -101.66M▼ 744.4% | -122.76M▼ 20.8% | -242.81M▼ 97.8% | -125.04M▲ 48.5% | -161.65M▼ 29.3% | -124.55M▲ 23.0% | -277.02M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -12.04M▲ 0% | -101.66M▼ 744.4% | -122.76M▼ 20.8% | -242.81M▼ 97.8% | -125.04M▲ 48.5% | -161.65M▼ 29.3% | -124.55M▲ 23.0% | -277.02M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -744.35% | -20.76% | -97.78% | 48.5% | -29.28% | 22.95% | -75.78% |
Net Income (Continuing) | -12.04M | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M | -124.55M | -277.02M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.10▲ 0% | -0.85▼ 750.0% | -1.03▼ 21.2% | -1.99▼ 93.2% | -0.83▲ 58.3% | -0.69▲ 16.9% | -0.44▲ 36.2% | -0.91▲ 0% |
EPS Growth % | - | -750% | -21.18% | -93.2% | 58.29% | 16.87% | 36.23% | -50% |
EPS (Basic) | -0.10 | -0.85 | -1.03 | -1.99 | -0.83 | -0.69 | -0.44 | - |
Diluted Shares Outstanding | 118.96M | 118.96M | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M | 304.32M |
Basic Shares Outstanding | 118.96M | 118.96M | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M | 304.32M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ERAS Balance Sheet
Erasca, Inc. (ERAS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 51.12M | 119.99M | 420.02M | 444.5M | 320.68M | 308.79M | 286.24M | 253.78M |
Cash & Short-Term Investments | 50.37M | 118.7M | 414.48M | 435.62M | 312.35M | 298.31M | 276.07M | 243.79M |
Cash Only | 29.58M | 65.38M | 360.49M | 284.22M | 93.08M | 67.74M | 73.81M | 47.26M |
Short-Term Investments | 20.79M | 53.33M | 53.99M | 151.4M | 219.28M | 230.57M | 202.27M | 196.53M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 2.3M | 2.5M | 3.3M |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 1.29M | 100K | 748K | 1.1M | 8.18M | 7.66M | 6.7M |
Total Non-Current Assets | 4.39M | 4.83M | 81.4M | 70.41M | 74.62M | 193.73M | 109.92M | 207.45M |
Property, Plant & Equipment | 4.33M | 4.07M | 33.31M | 65.23M | 60.19M | 48.54M | 42.33M | 40.88M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 312K | 44.77M | 2M | 10.05M | 142.16M | 66.13M | 392.14M |
Other Non-Current Assets | 56K | 451K | 3.32M | 3.18M | 4.38M | 3.03M | 1.45M | 1.45M |
Total Assets | 55.51M▲ 0% | 124.83M▲ 124.9% | 501.42M▲ 301.7% | 514.91M▲ 2.7% | 395.3M▼ 23.2% | 502.53M▲ 27.1% | 396.15M▼ 21.2% | 461.23M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 124.86% | 301.69% | 2.69% | -23.23% | 27.13% | -21.17% | -59.09% |
Total Current Liabilities | 2.75M | 13.68M | 26.22M | 48.69M | 26.16M | 31.39M | 28.51M | 26.66M |
Accounts Payable | 1.38M | 878K | 4.68M | 23.05M | 2M | 468K | 981K | 2.16M |
Days Payables Outstanding | - | - | 2.06K | 3.19K | 195.61 | - | 115.24 | 487.75 |
Short-Term Debt | 0 | 877K | 0 | 0 | 0 | 0 | 5.07M | 5.25M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 447K | 9.51M | 4.16M | 2.33M | 10.78M | 0 | 22.46M | 19.25M |
Current Ratio | 18.59x | 8.77x | 16.02x | 9.13x | 12.26x | 9.84x | 10.04x | 9.52x |
Quick Ratio | 18.59x | 8.77x | 16.02x | 9.13x | 12.26x | 9.84x | 10.04x | 9.52x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 66.37M | 3.72M | 18.66M | 54.37M | 52.45M | 47.63M | 42.47M | 41.04M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 2.96M | 2.11M | 18.51M | 53.79M | 51.89M | 47.27M | 42.07M | 170.9M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 63.4M | 1.61M | 158K | 573K | 566K | 362K | 399K | 340K |
Total Liabilities | 69.12M | 17.4M | 44.89M | 103.06M | 78.61M | 79.03M | 70.98M | 67.71M |
Total Debt | 3.69M | 2.99M | 18.79M | 55.1M | 55.86M | 51.89M | 47.14M | 45.95M |
Net Debt | -25.89M | -62.39M | -341.7M | -229.12M | -37.22M | -15.85M | -26.67M | -1.3M |
Debt / Equity | - | 0.03x | 0.04x | 0.13x | 0.18x | 0.12x | 0.14x | 0.12x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.33x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.01x |
Interest Coverage | - | - | - | -1.21x | - | - | - | - |
Total Equity | -13.6M▲ 0% | 107.42M▲ 889.6% | 456.53M▲ 325.0% | 411.85M▼ 9.8% | 316.69M▼ 23.1% | 423.5M▲ 33.7% | 325.17M▼ 23.2% | 393.53M▲ 0% |
Equity Growth % | - | 889.63% | 324.99% | -9.79% | -23.11% | 33.73% | -23.22% | -64.89% |
Book Value per Share | -0.11 | 0.90 | 3.83 | 3.38 | 2.11 | 1.81 | 1.15 | 1.29 |
Total Shareholders' Equity | -13.6M | 107.42M | 456.53M | 411.85M | 316.69M | 423.5M | 325.17M | 393.53M |
Common Stock | 3K | 3K | 12K | 15K | 15K | 28K | 28K | 31K |
Retained Earnings | -13.74M | -115.4M | -238.17M | -480.97M | -606.01M | -767.66M | -892.21M | -1.08B |
Treasury Stock | -124K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 11K | 2K | -162K | -1.04M | 77K | 405K | 628K | -699K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ERAS Cash Flow Statement
Erasca, Inc. (ERAS) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.38M | -32.69M | -79.6M | -103.26M | -101.22M | -109.42M | -95.45M | -91.28M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -214.95% | -143.53% | -29.73% | 1.98% | -8.1% | 12.76% | 57.88% |
Net Income | -12.04M | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M | -124.55M | -277.02M |
Depreciation & Amortization | 310K | 540K | 829K | 2.64M | 3.73M | 3.81M | 3.11M | 3.01M |
Stock-Based Compensation | 122K | 797K | 8.33M | 20.11M | 26.23M | 26.97M | 24.9M | 18.19M |
Deferred Taxes | 0 | 0 | -1.51M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -483K | 64.35M | 27.81M | 101.01M | -6.95M | 19.72M | 4.41M | 164.07M |
Working Capital Changes | 1.71M | 3.29M | 7.71M | 15.79M | 813K | 1.74M | -3.33M | 477K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.17M | -380K | 1.34M | 676K | -886K | -1.53M | 513K | -99K |
Cash from Investing | -20.89M | -71.2M | -64.59M | -71.08M | -91.22M | -156.62M | 100.42M | -177.67M |
Capital Expenditures | -597K | -947K | -18.89M | -16.55M | -1.77M | -60K | -128K | -81K |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 7.68M | 4M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | -37.74M | -7.68M | -4M | -20M | -22.5M | -9.5M | -159.5M |
Cash from Financing | 16.86M | 139.99M | 439.4M | 98.08M | 1.29M | 240.7M | 1.1M | 245.73M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 16.86M | 136.97M | 436.39M | 95.25M | 1.29M | 239.06M | 1.1M | 245.73M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 3.02M | 3M | 2.82M | 0 | 1.64M | 0 | 0 |
Net Change in Cash | -14.4M▲ 0% | 36.1M▲ 350.7% | 295.21M▲ 717.6% | -76.27M▼ 125.8% | -191.14M▼ 150.6% | -25.34M▲ 86.7% | 6.07M▲ 123.9% | -23.23M▲ 0% |
Free Cash Flow | -10.97M▲ 0% | -71.38M▼ 550.4% | -98.48M▼ 38.0% | -119.81M▼ 21.7% | -102.99M▲ 14.0% | -131.98M▼ 28.1% | -95.58M▲ 27.6% | -91.36M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -550.37% | -37.98% | -21.66% | 14.04% | -28.14% | 27.58% | 15.26% |
FCF per Share | -0.09 | -0.60 | -0.83 | -0.98 | -0.69 | -0.56 | -0.34 | -0.30 |
FCF Conversion (FCF/Net Income) | 0.86x | 0.32x | 0.65x | 0.43x | 0.81x | 0.68x | 0.77x | 0.33x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 13K | 69K | 0 | 0 | 0 | 0 | 0 | 0 |
ERAS Key Ratios
Erasca, Inc. (ERAS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -216.72% | -43.54% | -55.92% | -34.33% | -43.68% | -33.27% | -77.01% |
Return on Invested Capital (ROIC) | -2961.83% | -117.18% | -124.74% | -45.93% | -39.2% | -27.91% | -31.3% |
Debt / Equity | 0.03x | 0.04x | 0.13x | 0.18x | 0.12x | 0.14x | 0.12x |
Interest Coverage | - | - | -1.21x | - | - | - | - |
FCF Conversion | 0.32x | 0.65x | 0.43x | 0.81x | 0.68x | 0.77x | 0.33x |
Related:ERAS Dividend History·ERAS Revenue History·ERAS Price History·ERAS P/E History·ERAS Financial Ratios·ERAS Institutional Holders
ERAS SEC Filings & Documents
Erasca, Inc. (ERAS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ERAS Frequently Asked Questions
Erasca, Inc. (ERAS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Erasca, Inc. (ERAS) grew revenue by 0.0% over the past year. Growth has been modest.
Erasca, Inc. (ERAS) reported a net loss of $277.0M for fiscal year 2025.
Dividend & Returns
Erasca, Inc. (ERAS) has a return on equity (ROE) of -33.3%. Negative ROE indicates the company is unprofitable.
Erasca, Inc. (ERAS) had negative free cash flow of $91.4M in fiscal year 2025, likely due to heavy capital investments.